Protagenic Therapeutics, Inc. (PTIX)

$0.372

+0.05 (+16.21%)
Rating:
Recommendation:
-
Symbol PTIX
Price $0.372
Beta 0.200
Volume Avg. 0.02M
Market Cap 6.430M
Shares () -
52 Week Range 0.3111-1.05
1y Target Est -
DCF Unlevered PTIX DCF ->
DCF Levered PTIX LDCF ->
ROE -44.83% Strong Sell
ROA -46.58% Strong Sell
Operating Margin -
Debt / Equity 11.82% Neutral
P/E -1.77 Sell
P/B 0.87 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PTIX news


Dr. Garo H. Armen Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.